Patent ID: 6815175
Filing Date: 2004-11-09
Classification: A61K,A61P,C07K,G01N

Abstract:
A method for assessing risk of Alzheimer's Disease in a subject, which method comprises:determining the level of anti-&bgr;-amyloid-42 (A&bgr;42) antibody in a biological sample selected from the group consisting of blood, serum, and plasma from a subject, comparing the level of anti-A&bgr;42 antibody in the biological sample from the subject to a normal level determined from an average of the level of anti-A&bgr;42 antibody in a biological sample from a population consisting of age-matched normal subjects who do not show any symptoms of neurodegenerative disease or disorder associated with amyloidosis, wherein a statistically simificantly lower level in the biological sample from the subject indicates the risk of Alzheimer's Disease.